Consideration of stratification in confirmatory trials with time-to-event endpoint

被引:0
|
作者
Wang, Yizhuo [1 ]
Zhou, Xuan [2 ]
Guo, Zifang [2 ]
Fang, Xiao [2 ]
Liu, Fang [2 ]
Shen, Liji [2 ]
机构
[1] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA
[2] Merck & Co Inc, Biostat & Res Decis Sci, North Wales, PA 19454 USA
关键词
Stratification; Stratified analysis; Time-to-event; PEMBROLIZUMAB PLUS CHEMOTHERAPY; COLLAPSIBILITY; MODEL;
D O I
10.1016/j.cct.2024.107434
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Stratification in randomization and analysis are widely employed to balance treatment groups in clinical trials. However, the potential power loss due to under-stratification or over-stratification has not been thoroughly evaluated in the typical setting of confirmatory clinical trials. In cases where there are too many strata and some have small sample sizes or a small number of events, it is common practice to combine these small strata during analysis. However, there is a lack of guidance on how those small strata should be combined. This paper presents extensive simulation studies to evaluate the impact of under-stratification or over-stratification on the power of survival analysis and the estimate of hazard ratio using stratified log-rank test and Cox PH model, respectively. The difference in power between stratified and unstratified log-rank tests is also investigated under different scenarios. Our results suggest that failing to consider prognostic stratification factors with strong effects, and/or accounting for non-prognostic factors such as noise and predictive factors, may reduce the power of the stratified log-rank test. Additionally, methods of combining small strata are explored and compared.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Milestone prediction for time-to-event endpoint monitoring in clinical trials
    Ou, Fang-Shu
    Heller, Martin
    Shi, Qian
    [J]. PHARMACEUTICAL STATISTICS, 2019, 18 (04) : 433 - 446
  • [2] A Bayesian adaptive design for biosimilar trials with time-to-event endpoint
    Belay, Sheferaw Y.
    Mu, Rongji
    Xu, Jin
    [J]. PHARMACEUTICAL STATISTICS, 2021, 20 (03) : 597 - 609
  • [3] Predicting study duration in clinical trials with a time-to-event endpoint
    Machida, Ryunosuke
    Fujii, Yosuke
    Sozu, Takashi
    [J]. STATISTICS IN MEDICINE, 2021, 40 (10) : 2413 - 2421
  • [4] Group sequential testing for cluster randomized trials with time-to-event endpoint
    Li, Jianghao
    Jung, Sin-Ho
    [J]. BIOMETRICS, 2022, 78 (04) : 1353 - 1364
  • [5] CONFIRMATORY ADAPTIVE DESIGNS FOR SURVIVAL TRIALS WITH SEVERAL TIME-TO-EVENT ENDPOINTS
    Schmidt, Rene
    [J]. NEURO-ONCOLOGY, 2022, 24 : 187 - 187
  • [6] Sample size calculation for cluster randomization trials with a time-to-event endpoint
    Li, Jianghao
    Jung, Sin-Ho
    [J]. STATISTICS IN MEDICINE, 2020, 39 (25) : 3608 - 3623
  • [7] Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations
    McCaw, Zachary R.
    Kim, Dae Hyun
    Wei, Lee-Jen
    [J]. JNCI CANCER SPECTRUM, 2022, 6 (01)
  • [8] Guidelines for time-to-event endpoint definitions in randomized cancer trials for sarcomas and GIST: Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
    Bellera, C.
    Ouali, M.
    Penel, N.
    Litiere, S.
    Casali, P.
    Bonvalot, S.
    Nielsen, O. S.
    Delannes, M.
    Mathoulin-Pelissier, S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S881 - S881
  • [9] Adaptive Biomarker Population Selection in Phase III Confirmatory Trials with Time-to-Event Endpoints
    Li X.
    Chen C.
    Li W.
    [J]. Statistics in Biosciences, 2018, 10 (2) : 324 - 341
  • [10] A ratio test in active control non-inferiority trials with a time-to-event endpoint
    Wang, YC
    Chen, G
    Chi, GYH
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2006, 16 (02) : 151 - 164